Billiontoone (NASDAQ:BLLN) Stock Price Target Lowered at Piper Sandler

Posted by Stanley Muller on Nov 10th, 2026

Billiontoone (NASDAQ:BLLN – Get Free Report) had its price target dropped by research analysts at Piper Sandler from $140.00 to $130.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s target price suggests a potential upside of 13.09% from the company’s previous close.

BLLN has been the subject of several other research reports. Zacks Research raised shares of Billiontoone from a “strong sell” rating to a “hold” rating in a report on Friday, October 2nd. Guggenheim raised their target price on shares of Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings downgraded shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. BTIG Research restated a “buy” rating and set a $130.00 price target on shares of Billiontoone in a research report on Thursday, November 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of Billiontoone from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, November 5th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Billiontoone presently has an average rating of “Moderate Buy” and an average price target of $124.38.

Check Out Our Latest Stock Analysis on BLLN

Billiontoone Trading Up 0.9%

NASDAQ:BLLN opened at $114.95 on Tuesday. Billiontoone has a 1 year low of $61.96 and a 1 year high of $150.44. The stock has a market cap of $5.42 billion and a price-to-earnings ratio of 123.79. The business has a fifty day moving average of $105.80 and a 200-day moving average of $97.30. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69.

Insider Transactions at Billiontoone

In related news, CEO Oguzhan Atay sold 25,001 shares of Billiontoone stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $109.24, for a total transaction of $2,731,109.24. Following the transaction, the chief executive officer directly owned 16,667 shares of the company’s stock, valued at $1,820,703.08. The trade was a 60.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 2,834 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $113.17, for a total transaction of $320,723.78. Following the completion of the sale, the senior vice president owned 16,551 shares in the company, valued at approximately $1,873,076.67. This trade represents a 14.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 252,777 shares of company stock valued at $26,737,151. Corporate insiders own 50.22% of the company’s stock.

Hedge Funds Weigh In On Billiontoone

Several hedge funds have recently made changes to their positions in the business. Aberdeen Group plc bought a new stake in Billiontoone during the third quarter worth approximately $19,565,000. Three Bridge Wealth Advisors LLC acquired a new position in Billiontoone in the third quarter worth approximately $275,000. Penn Capital Management Company LLC increased its holdings in shares of Billiontoone by 2.3% in the third quarter. Penn Capital Management Company LLC now owns 132,636 shares of the company’s stock valued at $14,143,000 after buying an additional 3,034 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Billiontoone by 86.7% in the third quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $30,000 after buying an additional 130 shares in the last quarter. Finally, Provenance Wealth Advisors LLC bought a new position in shares of Billiontoone in the third quarter valued at $56,000.

About Billiontoone

(Get Free Report)

BillionToOne is a molecular diagnostics company that develops and provides genetic testing for prenatal care and cancer care. Its tests use the company’s molecular counting technology to detect and measure genetic material in patient samples.

In prenatal care, BillionToOne offers screening for chromosomal conditions and certain inherited single-gene disorders. Its UNITY platform includes tests designed to assess fetal risk using a pregnant patient’s blood sample.

The company also provides oncology testing, including services designed to help characterize tumors and detect cancer-related genetic material.